Dexcom (DXCM) Expected to Post Earnings of -$0.32 Per Share

Equities research analysts predict that Dexcom (NASDAQ:DXCM) will announce earnings of ($0.32) per share for the current fiscal quarter, according to Zacks. Eleven analysts have issued estimates for Dexcom’s earnings, with the lowest EPS estimate coming in at ($0.43) and the highest estimate coming in at ($0.10). Dexcom reported earnings per share of ($0.49) during the same quarter last year, which suggests a positive year-over-year growth rate of 34.7%. The company is scheduled to report its next quarterly earnings report after the market closes on Wednesday, May 2nd.

According to Zacks, analysts expect that Dexcom will report full-year earnings of ($0.55) per share for the current financial year, with EPS estimates ranging from ($0.81) to ($0.27). For the next year, analysts expect that the business will post earnings of ($0.23) per share, with EPS estimates ranging from ($0.73) to $0.02. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Dexcom.

How to Become a New Pot Stock Millionaire

Dexcom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, February 27th. The medical device company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.07. The firm had revenue of $221.00 million during the quarter, compared to analysts’ expectations of $217.82 million. Dexcom had a negative return on equity of 13.99% and a negative net margin of 6.99%.

DXCM has been the subject of several research reports. BidaskClub raised Dexcom from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 4th. Northland Securities downgraded Dexcom from a “market perform” rating to an “under perform” rating and set a $85.00 price target for the company. in a research report on Thursday, January 4th. Barclays reissued a “hold” rating and set a $60.00 price target on shares of Dexcom in a research report on Monday, January 8th. ValuEngine downgraded Dexcom from a “hold” rating to a “sell” rating in a research report on Thursday, February 8th. Finally, Oppenheimer set a $67.00 price target on Dexcom and gave the stock a “buy” rating in a research report on Monday, February 12th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $67.38.

Shares of DXCM stock opened at $73.73 on Thursday. The firm has a market cap of $6,455.87, a P/E ratio of -127.12 and a beta of -0.01. Dexcom has a 1 year low of $42.62 and a 1 year high of $81.91. The company has a quick ratio of 5.04, a current ratio of 5.36 and a debt-to-equity ratio of 0.78.

In other news, EVP Richard Doubleday sold 1,638 shares of Dexcom stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $56.32, for a total value of $92,252.16. Following the completion of the sale, the executive vice president now owns 65,049 shares of the company’s stock, valued at $3,663,559.68. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Terrance H. Gregg sold 10,000 shares of Dexcom stock in a transaction on Monday, April 16th. The shares were sold at an average price of $73.04, for a total value of $730,400.00. Following the completion of the sale, the insider now directly owns 521,674 shares of the company’s stock, valued at approximately $38,103,068.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 36,800 shares of company stock valued at $2,402,141. Company insiders own 1.70% of the company’s stock.

Several large investors have recently made changes to their positions in DXCM. American International Group Inc. purchased a new stake in shares of Dexcom in the fourth quarter valued at $116,000. Thompson Davis & CO. Inc. purchased a new stake in shares of Dexcom in the fourth quarter valued at $137,000. Marco Investment Management LLC purchased a new stake in shares of Dexcom in the fourth quarter valued at $201,000. D.A. Davidson & CO. purchased a new stake in shares of Dexcom in the fourth quarter valued at $208,000. Finally, First Manhattan Co. purchased a new stake in shares of Dexcom in the fourth quarter valued at $223,000.

WARNING: “Dexcom (DXCM) Expected to Post Earnings of -$0.32 Per Share” was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://weekherald.com/2018/04/26/dexcom-dxcm-expected-to-post-earnings-of-0-32-per-share.html.

About Dexcom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Get a free copy of the Zacks research report on Dexcom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dexcom (NASDAQ:DXCM)

Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply